Delving into the Latest Updates on Fentanyl Citrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Abstral Sublingual, E-Fen Buccal, Fentanyl citrate (JP17/USP)

+ [33]

Target

μ opioid receptor

Action

agonists

Mechanism

μ opioid receptor agonists(Mu opioid receptor agonists)

Therapeutic Areas

Nervous System DiseasesUrogenital DiseasesOther Diseases

Active Indication

Breakthrough PainCancer PainHyperemesis Gravidarum+ [1]

Inactive Indication

Anemia, Sickle CellBurnsChronic Pain+ [4]

Originator Organization

Rising Pharmaceuticals, Inc.Startup

Active Organization

Teva Pharmaceuticals Europe BV

Grünenthal GmbH

Istituto Gentili Srl

+ [5]

Inactive Organization

BTcP Pharma LLC

Cephalon, Inc.

BioDelivery Sciences International, Inc.

+ [5]

Drug Highest PhaseApproved

First Approval Date

United States (19 Feb 1968),

Anesthesia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC28H36N2O8

InChIKeyIVLVTNPOHDFFCJ-UHFFFAOYSA-N

CAS Registry990-73-8

Injury and deformity of the upper extremity can result in dysfunction to nerves, tendons and bones which can lead to disability and pain.
Various techniques of regional anesthesia are frequently used for upper extremity surgery. Specifically, intravenous regional anesthesia, the Bier block, is an effective anesthetic technique. This technique, developed by Dr August Bier in 1908, provides complete anesthesia, a bloodless field, and eliminates the need for general anesthesia. However, it was not until the 1960s that this technique was reintroduced and used in upper extremity surgery due to several disadvantages and reports of major complications. Because of the dose of lidocaine and tourniquet time, there is potential for cardiac and neurological complications such as arrhythmias, seizures, and compartment syndrome the aim of this study To evaluate the effect of Systemic Fentanyl Infusion compared to addition of Fentanyl as An Adjuvant to Lidocaine in Bier Block for Controlling Pain in Patients Undergoing Hand Surgeries

Start Date01 Jul 2025

Sponsor / Collaborator

Assiut University

CTRI/2025/03/082720

/ Not yet recruitingNot ApplicableIIT

A Comparative Study Between Intrathecal Ropivacaine Alone Versus Synergistic Effect Of Intrathecal Fentanyl And Ropivacaine In Spinal Anaesthesia For Caesarean Section - NIL

Start Date28 Apr 2025

Sponsor / Collaborator

Prachi Hospital

CTRI/2025/03/083648

/ Not yet recruitingPhase 3IIT

Evaluation of Analgesic efficacy of Errector spinar plane block for Percutaneous Nephrolithotomy - Nil

Start Date25 Apr 2025

Sponsor / Collaborator-

100 Clinical Results associated with Fentanyl Citrate

Login to view more data

100 Translational Medicine associated with Fentanyl Citrate

Login to view more data

100 Patents (Medical) associated with Fentanyl Citrate

Login to view more data

12,206

Literatures (Medical) associated with Fentanyl Citrate

01 Jun 2025·Analytical science advances

Development and Validation of a Gas Chromatography‐Mass Spectrometry Method for the Determination of Fentanyl and Butyryl Fentanyl in Oral Fluid

Article

Author: Anzillotti, Luca ; Cecchi, Rossana ; Camedda, Nicola ; Dagoli, Sara

ABSTRACT:

Synthetic opioids are lab‐synthesized substances that target the brain's opioid receptors, offering analgesic and sedative effects. Amongst them, fentanyl is one of the most widely used to intervene in chronic pain in moderate to severe cancer situations. Butyryl fentanyl (BF) is a novel synthetic opioid whose use is growing. Its potency is seven times that of morphine and, unlike fentanyl, BF can only be obtained through illegal sources. Fentanyl and its analogues are related to harmful intoxications and an increase in opioid‐related mortality in many countries, such as in the United States and Europe in recent years. This work developed and validated an effective and sensitive method based on solid‐phase extraction followed by gas chromatography‐mass spectrometry (GC‐MS) for the determination of fentanyl and BF in oral fluid samples. To the best of our knowledge, it is the first successful attempt to quantify these analytes using GC‐MS with a limit of quantification (LOQ) of 1 ng/mL in OF. Intra‐day and inter‐day percentage coefficient of variation were found within 1%–3% and 1%–14%, respectively, while accuracy ranged from 92% to 102% at four concentration levels (lower LOQ [LLOQ], 3, 20, 40 ng/mL) in accordance with the established criteria. The absolute recovery values were in the range of 80.0%–100.0%. The method was linear for all analytes, with quadratic regression of calibration curves always higher than 0.99. The validated method demonstrated its great potential to detect and quantify fentanyl and its analogue in OF and it can be useful not only in forensic investigations of addiction histories but also in epidemiological studies on the spread of fentanyl and BF among workers and/or drivers.

01 Jun 2025·FOOD CHEMISTRY

High-throughput screening of new psychoactive substances and related compounds in food by UHPLC-Q/Orbitrap

Article

Author: Huang, Xia ; Wan, Yuping ; Shi, Peiyu ; Wu, Wenlin ; Xiao, Quanwei ; Liu, Shiyao ; Guo, Tianrong ; Chen, Xiaoqi ; Zhang, Min ; Zhou, Yan ; Xia, Bing

Currently, there is concern about food products to which new psychoactive substances (NPS) have been added illegally. However, rapid, high-sensitivity, and high-throughput screening methods for such harmful substances have not been reported yet. In this study, a high-throughput non-targeted screening strategy was developed based on UHPLC-Q/Orbitrap. First, optimized pretreatment methods for typical high-risk matrices were established. Second, an accurate, efficient, and scalable high resolution mass spectrometry database containing 206 NPS and related compounds was constructed. The fragmentation pathways of three different types of fentanyl-related compounds were then systematically investigated to enhance compound identification. Additionally, a non-targeted screening strategy was developed using warning ions derived from 24 fentanyl-related compounds, streamlining the identification of NPS. This strategy was applied to 100 food samples with possible illegal additives and demonstrated its effectiveness. In summary, this study provides robust technical support for regulatory authorities in combating the illegal addition of food products.

01 Jun 2025·NEUROPHARMACOLOGY

Comparison of fentanyl-induced brain oxygen responses following intravenous and intraperitoneal injections in rats

Article

Author: Limiac, Feonil G ; Kiyatkin, Eugene A ; Noya, Michael R

This study used oxygen sensors coupled with amperometry to examine changes in brain (nucleus accumbens) and peripheral (subcutaneous space) oxygen levels following intravenous (IV) and intraperitoneal (IP) fentanyl injections at different doses. To avoid stress associated with traditional IP injection, fentanyl was delivered via chronically implanted IP catheter. SC oxygen levels decreased in a dose-dependent monophasic manner, whereas brain oxygen responses were more complex, showing modest increases at low fentanyl doses (<3 μg/kg for IV and <10 μg/kg for IP) and biphasic effects (decrease followed by increase) at higher doses (≥10 μg/kg for IV and ≥270 μg/kg for IP). IV-delivered fentanyl elicited faster and stronger responses, with over 10-fold greater potency to induce brain hypoxia compared to IP-fentanyl. Although oxygen response patterns were similar between catheter-based and traditional needle IP injection, the latter caused an ultra-fast brain oxygen increase coupled with rapid oxygen decrease in SC space, suggesting stress as a contributing factor. Interestingly, low-dose, stress-free IP fentanyl administration also induced phasic brain oxygen increases coupled with robust but transient behavioral activation, the effect appears to be independent of drug action on opioid receptors. This effect was attributed to the acidity of fentanyl citrate solution (pH 4.8) and direct actions of H+ on receptive sites on afferents of sensory nerves innervating the abdominal cavity. These findings reveal distinct fentanyl-induced oxygen dynamics based on administration route and highlight the influence of injection stress and drug formulation on oxygen and behavioral responses.

30

News (Medical) associated with Fentanyl Citrate

07 Apr 2025

·www.prnewswire.com

Elysium Therapeutics Announces Development of Overdose Rescue Technology Specifically Designed for Oral Fentanyl

Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) targets an unmet challenge in the illicit opioid crisis as current rescue medications are not designed for synthetic opioids, including oral fentanyl. LYONS, Colo., April 7, 2025 /PRNewswire/ -- Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral opioids, including synthetic opioids like fentanyl, announced its plan to accelerate development of its Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology. The company has completed in vivo proof-of-concept studies and expects to file an Investigational New Drug (IND) application in 2026. SOOPR is a rapid-onset, long-acting rescue agent specifically designed to address overdose from synthetic opioids, including oral fentanyl. SOOPR utilizes a proprietary long-acting naloxone prodrug formulation with faster onset kinetics versus Narcan® delivered via long-acting injection (LAI) technology. The technology is designed to rapidly restore respiration and provide 18 to 24 hours of effective opioid blockade to minimize the risk of re-narcotization, while also providing protection from same-day re-use of opioids. "Fentanyl overdoses often require very high, or repeated, doses of short-acting opioid antagonists to effect a successful rescue," said Greg Sturmer, Co-Founder and CEO of Elysium Therapeutics. "Unfortunately, many who overdose face a rapid recurrence of symptoms, known as re-narcotization, which can lead to respiratory depression and increase the likelihood of hypoxic brain injury or death. SOOPR is designed to address this situation, and Elysium is now focused on advancing its development as a potential first-ever, faster-onset, longer-acting opioid rescue therapy specifically intended to treat fentanyl overdose." Currently approved short-acting opioid antagonists like Narcan and Opvee® were designed to effectively counteract overdoses from opioids such as heroin and oxycodone. However, these rescue agents are frequently ineffective in the management of synthetic opioid overdoses1, with 20 to 45% of overdose victims initially rescued with naloxone experiencing a re-narcotization event. According to reports from multiple state-affiliated health agencies, 31 to 39% of fentanyl overdose decedents had been administered naloxone.2 Data from in vivo proof-of-concept studies of SOOPR demonstrated a more rapid onset of action versus naloxone (Narcan) and a significantly longer duration of action. This profile is especially useful in counteracting oral fentanyl overdoses associated with prolonged fentanyl absorption and exposure that often outlast the short-acting profile of Narcan. "In designing SOOPR, Elysium recognized that synthetic opioids – now the number one killer of adults aged 18 to 45 in the U.S. – are particularly lethal," said Tom Jenkins, Ph.D., Co-Founder and Chief Scientific Officer of Elysium Therapeutics. "Patients initially treated with a rapid-acting, long-duration reversal agent, such as SOOPR, are expected to have less risk of hypoxic brain injury, cardiovascular events, re-narcotization, and death. Further, rescue interventions with SOOPR are expected to require less intensive monitoring in both the ambulance and emergency department and increase the likelihood of survival. Additionally, SOOPR is designed to be delivered by intramuscular injection, either using a pre-filled syringe or autoinjector, which has been demonstrated to be more rapid and predictable than intranasal delivery in urgent settings, where every second counts." "In addition to preventing overdose deaths from recreational, illicit use, the Department of Defense (DOD) has made clear the importance of improving opioid overdose rescue as a needed medical countermeasure," added Sturmer. "The DOD reported that the availability of synthetic opioids, such as fentanyl and its derivatives, represents a significant threat as a chemical weapon, which could be easily disseminated as a weapon of mass destruction into air, water or food supplies, putting countless lives at risk. We look forward to working with defense and government organizations as we develop SOOPR as a tool to prevent injury and death in these worrisome scenarios." About SOOPR™ (Synthetic Opioid Overdose Prevention and Rescue) SOOPR (Synthetic Opioid Overdose Prevention and Reversal) is a rapid-onset, long-acting rescue agent specifically designed to address overdose from synthetic opioids, including oral fentanyl. SOOPR utilizes a proprietary long-acting naloxone reversal formulation with faster onset kinetics versus Narcan® delivered via long-acting injection (LAI) technology. The technology is designed to rapidly restore respiration and provide 18 – 24 hours of effective opioid blockade to minimize the risk of re-narcotization, while also providing protection from same-day re-use of opioids. SOOPR has been endorsed by first responders and OUD treatment professionals as the effective solution urgently needed to address the global opioid overdose epidemic. About Elysium Therapeutics Elysium is an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral synthetic opioids, including fentanyl. Elysium is working to establish new standards of safety in the opioid industry by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines that address the limitations and dangers associated with opioids and overdose rescue agents to reduce suffering from opioid-use disorder, opioid overdose, and acute pain. Elysium's lead technology, SOOPR™ (Synthetic Opioid Overdose Prevention and Reversal), is a long-acting opioid antagonist specifically designed to address oral synthetic opioid, including fentanyl, overdose. Tens of thousands of unnecessary overdose deaths each year exemplifies the critical shortcomings of currently available rescue agents, including naloxone and nalmefene. In addition, Elysium is developing oral-overdose protected (O2P™) hydrocodone for the treatment of moderate-to-severe acute pain. For more information, please visit . 1 Rachael Rzasa Lynn and JL Galinkin Ther Adv Drug Saf 2018, Vol. 9(1) 63–88 (Also see footnotes 8, 9, and 10 for additional discussion). 2 Watson, W.A., Steele, M.T., Muelleman, R.L., Rush, M.D., 1998. Opioid toxicity recurrence after an initial response to naloxone. J. Toxicol. Clin. Toxicol. 36 (1-2), 11–17. . SOURCE Elysium Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

24 Mar 2025

·www.biospace.com

Tempero Raises $70M to Fight Substance Use Disorders

iStock, Anatolii Frolov The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat alcohol- and cocaine-use disorders, among other indications. Tempero Bio, a Bay Area–based biotech, has raised $70 million in Series B financing to develop therapies for substance use disorders. The financing round, announced Monday, will push the company’s lead molecule TMP-301 through two Phase II clinical trials for alcohol- and cocaine-use disorders, on top of “Phase III-enabling activities” for other indications and formulations. “Substance use disorders affect 48 million Americans and contribute to more than 100,000 deaths per year.  We urgently need more effective treatments to help patients and families with these diseases,” Tempero CEO and President Ricardo Dolmetsch said in a company statement. “TMP-301 is a novel therapy that helps prevent relapse by targeting the underlying biology of addiction.” Tempero was birthed from a 2020 partnership between Aditum Bio (Tempero’s continuing benefactor) and Soshei Heptares (now known as Nxera). Aditum is an investment firm run by Joe Jimenez, former CEO of Novartis, and Mark Fishman, former head of the pharma’s R&D hub, known as Novartis Biomedical Research. Aditum funded Tempero, while Soshei licensed a suite of metabotropic glutamate receptor 5 (mGlu5) NAM modulator molecules, including TMP-301. These molecules modulate glutamate signaling in the brain, a pathway with potential applications in treating substance use disorders like alcohol abuse and smoking, as well as depression and certain neurodegenerative disorders . Tempero got investigational new drug (IND) clearance for TMP-301 in early 2023, as well as a $5.3 million grant from the National Institutes of Health to study it in cocaine use disorders. Tempero’s latest financing round, led by 8VC with additional money from Aditum Bio, Khosla Ventures and other undisclosed participants, is another sign of biopharma’s interest in developing medical treatments for substance use disorders. A variety of companies are attempting to directly neutralize a drug, like fentanyl, and its effect on the body, while others are looking to use GLP-1 drugs to reduce cravings. Altimmune, Novo Nordisk and Eli Lilly are all currently conducting or preparing for clinical trials targeting alcohol-use disorders using GLP-1s.

Phase 2Phase 3

03 Feb 2025

·www.fiercepharma.com

Alvogen recalls fentanyl patches due to possible overdose risk

The patches in question were manufactured by Kindeva Drug Delivery and distributed by Alvogen across the U.S. to pharmacies and patients. When it comes to the safe use of synthetic opioids like fentanyl, precise dosing of the powerful pain meds is key. Now, Alvogen is yanking one product in the U.S. thanks to a packaging error that's already yielded at least one major safety report. Alvogen has issued a voluntary recall on a single lot of fentanyl transdermal patches due to the risk that some of the products could be "multi-stacked" and stuck together in a single pouch.Patients who apply the stacked pouches run the risk of taking a higher dose than intended, potentially leading to serious, life-threatening or fatal breathing issues, Alvogen warned. First-time users of the patches, plus children and the elderly, are at greater risk of potential overdose incidents, the company added.So far, Alvogen says it has already received at least one "serious adverse event" report tied to the mispackaged products. The patches in question are used to manage severe and persistent pain in opioid-tolerant patients over an extended treatment period. The recall covers Lot 108319 of the transdermal patches, which were originally slated to expire in April 2027. The batch, containing cartons of five individually wrapped and labeled pouches, was manufactured by Kindeva Drug Delivery and distributed by Alvogen across the country to pharmacies and patients, according to a Jan. 31 press release.Alvogen is advising patients to immediately remove any patches in use and contact their healthcare providers. Unused patches should be returned to the point of purchase and swapped out for a replacement. The problem is not new to Alvogen, which recalled two lots of Fentanyl Transdermal System 12 mcg/h transdermal patches in April 2019 after discovering that “a small number of cartons” labeled as 12 mcg/h actually contained 50 mcg/h patches. Those lots were manufactured by 3M Drug Delivery Systems in St. Paul, Minnesota.Elsewhere, Hikma last summer recalled one batch of acetaminophen injection, a pain med, citing the “potential presence” of a bag labeled dexmedetomidine HCL in the wrong packaging.

100 Deals associated with Fentanyl Citrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01399	Fentanyl Citrate	N02AB03 N01AH01	DB00813

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pain	United States	Adalvo Ltd.	16 Jul 2009
Breakthrough Pain	European Union	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	Iceland	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	Liechtenstein	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	Norway	Teva Pharmaceuticals Europe BV	04 Apr 2008
Cancer Pain	United States	Cephalon, Inc.	04 Nov 1998
Hyperemesis Gravidarum	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Anesthesia	United States	Rising Pharmaceuticals, Inc.Startup	19 Feb 1968

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 3	Italy	L. Molteni & C. dei F.lli Alitti Società di Esercizio SpA	01 Sep 2014
Chronic Pain	Phase 3	United States	Cephalon, Inc.	01 Dec 2006
Low Back Pain	Phase 3	United States	Cephalon, Inc.	01 Sep 2005
Neuralgia	Phase 3	United States	Cephalon, Inc.	01 Sep 2005
Neoplasms	Phase 3	United States	Cephalon, Inc.	01 Apr 2004
Anemia, Sickle Cell	Phase 2	United States	Cephalon, Inc.	01 Oct 2006
Anemia, Sickle Cell	Phase 2	Canada	Cephalon, Inc.	01 Oct 2006
Anemia, Sickle Cell	Phase 2	Puerto Rico	Cephalon, Inc.	01 Oct 2006
Burns	Phase 2	United States	Cephalon, Inc.	01 Oct 2006
Burns	Phase 2	Canada	Cephalon, Inc.	01 Oct 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04230681 (CTgov)	Early Phase 1	Sleep Apnea, Obstructive \| Tonsillitis	189	Hydromorphone (Hydromorphone)	omigbubvpx = zlxvlcbyzb xyxkssgcfj (kuxulyvarl, yhsozihiti - nvmibvccpf) View more	-	18 Dec 2024
				Fentanyl (Fentanyl)	omigbubvpx = gzfjuvpbxk xyxkssgcfj (kuxulyvarl, iivvexbwvh - zgqgocfgec) View more
NCT03435003 (CTgov)	Phase 4	Postoperative Nausea and Vomiting \| Vomiting	83	dexmedetomidine+Compazine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+sugammadex+Reglan+Propofol+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm)	pjjdhtdxlj = ykrsisxgau eymwjroksj (ugjovokdng, ovmqbufqgc - khrwihhcxw) View more	-	14 Feb 2024
				Compazine+sugammadex+Reglan+Sevoflurane+Desflurane+Ondansetron+Dexamethasone (Control Arm)	pjjdhtdxlj = yriduqtakb eymwjroksj (ugjovokdng, vmxicgtpxw - hygftjeocb) View more
NCT01362998 (CTgov)	Not Applicable	Analgesia	2	morphine (Preservative Free Morphine)	jcwhmaczwx(iuoqzfhqdl) = abnostuqee kkyrxpdppx (xgjikixgzb, aaxieyegjn - bsdglkhptp) View more	-	14 Nov 2022
				Fentanyl (Fentanyl Infusion)	itnrwctyou = pelibaanem xliwxzdtkm (sktmfdrhtc, yeqzadqcli - wstleqtoza) View more
NCT02747875 (CV_RCT_M_F, CTgov)	Not Applicable	Pain, Postoperative	26	Fentanyl (Control - Fentanyl)	tvuvczantw(bjqaemssix) = gadumzvimj rulxqfqmmx (khdesnlubd, 0.21) View more	-	01 Jun 2021
				Methadone (Treatment - Methadone)	tvuvczantw(bjqaemssix) = sppzmbaisu rulxqfqmmx (khdesnlubd, 0.24) View more
NCT02056288 (CTgov)	Phase 4	Fractures, Bone \| Pain, Postoperative	78	Ropivacaine (Ultrasound Guided Supraclavicular Block)	hwoqvdxzsj(bnpisexysc) = pjjbqsszjt oskehbddjm (ukkyyowmkq, boydwzakfv - xqkxobwifm) View more	-	21 May 2021
				Fentanyl (IV Opioids)	hwoqvdxzsj(bnpisexysc) = mlkhjdpmjm oskehbddjm (ukkyyowmkq, fnexkcxrax - rnpesmihwc) View more
NCT01621230 (BUP, CTgov)	Phase 4	Pregnancy	481	Epidural fentanyl	ojxnzowreh = hskyycqggu ciqjgmajlm (zbczrouhbm, ghkmssezcc - etixniciop) View more	-	24 Aug 2020
NCT02862912 (CTgov)	Phase 4	Drug-Related Side Effects and Adverse Reactions \| Uterine Cervical Incompetence	43	Fentanyl+Chloroprocaine (Chloroprocaine (CP))	fhsjscorhc(ezzpspjhcz) = orrvgenjka auzdnhjcsm (vjeekohnhh, zzwejncsxi - dcujzvtqen) View more	-	26 May 2020
				Fentanyl+Bupivacaine+Saline (Bupivacaine (BUP))	fhsjscorhc(ezzpspjhcz) = ccemmbkkhm auzdnhjcsm (vjeekohnhh, upiasirncr - dtnenljqro) View more
NCT03307174 (CTgov)	Phase 4	Analgesia \| Acute Pain	120	Fentanyl+Bupivacaine (Continuous Epidural Infusion)	ezfuwpivnv(pschmcvzmj) = aqmtzwsvsd mpmkphagvt (ivpizlqbrk, zilpqlejns - lzvkivqyfa) View more	-	12 May 2020
				Fentanyl+Bupivacaine (Programmed Intermittent Epidural Bolus)	ezfuwpivnv(pschmcvzmj) = auvygeubuo mpmkphagvt (ivpizlqbrk, dynypglcny - obaeglybnp) View more
NCT02531971 (CTgov)	Phase 4	-	24	Duragesic (Duragesic)	clejjhbzuc(hqiukikpaa) = hsyaetwruv mzspdewexn (xxlvfktgnd, 31.6)	-	26 Mar 2020
				fentanyl (Mylan)	clejjhbzuc(hqiukikpaa) = ktwmimlhzq mzspdewexn (xxlvfktgnd, 35.1)